Related Experiment Video
Updated: Jun 9, 2025
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.5K
Microsatellite Instability and Clinical Use in Sarcomas: Systematic Review and Illustrative Case Report
Italo Fernandes1, Douglas Dias E Silva1, Vanderlei Segatelli1
1Hospital Israelita Albert Einstein, São Paulo, Brazil.
JCO Precision Oncology
|October 21, 2024
Summary
This study shows pembrolizumab can effectively treat deficient mismatch repair (dMMR) sarcomas, even in advanced cases. It also highlights challenges in accurately diagnosing dMMR/microsatellite instability-high (MSI-H) status across different testing methods.
Area of Science:
- Oncology
- Immunotherapy
- Genomic Medicine
Background:
- Sarcomas are heterogeneous cancers with variable responses to immunotherapy.
- Pembrolizumab is approved for dMMR/MSI-H tumors, but data in sarcomas is limited.
- Understanding dMMR/MSI-H status is crucial for guiding sarcoma treatment.
